Work Package 1 (WP1) of Neuronet carried out an impact analysis to assess the scientific and socio-economic impact of the IMI ND portfolio across the European Union (EU). The impact analysis was conducted in two stages: an initial stage developed the scope of the project, impact
indicators and defined measures, and this report details the second and final stage of the impact analysis including the conduct, reporting and results of two surveys: one to European Federation of Pharmaceutical Industries and Associations (EFPIA) organisations and another to ‘non-EFPIA’ organisations including academic institutions and small and medium sized enterprises.
D1.7 Final report on impact of IMI neurodegeneration portfolio
